Background: Very few studies have evaluated the global prevalence of pruritus.
Objectives: To assess its prevalence according to age, sex, ethnicity and geographic region.
Methods: An international cross-sectional study was conducted in 20 countries from January to April 2023. Participants were asked to complete a questionnaire on sociodemographics, and to confirm the presence or absence of a skin disease in the last 12 months and the presence or absence of pruritus in the last 7 days.
Results: The studied sample included 50 552 individuals. The worldwide prevalence of pruritus was 39.8%. The age group ≥ 65 years had the highest prevalence (43.3%). The prevalence was 40.7% among women and 38.9% among men (P < 0.001). There was no significant difference between ethnicities (P = 0.14). Compared with North America (41.2%), the prevalence of pruritus was significantly lower in Europe (35.9%, P < 0.001), Australia (38.4%, P = 0.017), East Asia (40.2%, P = 0.04) and Latin America (36.5%, P < 0.001), and higher in Africa (45.7%, P = 0.007). No significant difference was found with the Middle East (40.2%, P = 0.36). The prevalence of pruritus in BRICS countries (40.3%) was significantly higher than that in developed countries (38.7%) (P < 10-3).
Conclusions: Out analysis is limited because there is no information about the severity or type (acute, chronic) of pruritus. The global prevalence of pruritus revealed age, sex and geographic region differences, with no ethnic differences.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/bjd/ljae260 | DOI Listing |
JAAD Int
February 2025
Galderma, Zug, Switzerland.
Mycoses
December 2024
Working Group on Mycoses in DRC, Kinshasa, Democratic Republic of the Congo.
Background: Although cutaneous mycoses are a global public health problem, very few data are available in the Democratic Republic of Congo (DRC).
Objectives: This study aimed to describe the retrospective clinical epidemiology of dermatomycosis and their associated risk factors in dermatological consultations in Kinshasa, DRC.
Methods: A retrospective study based on the medical records of patients seen in the departments of dermatology of 2 major hospitals in Kinshasa from March 2000 to August 2023 was carried out.
Clin Cosmet Investig Dermatol
December 2024
Division of Dermatology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Background: Vitiligo is a common disease. Limited studies in Saudi Arabia have explored the detailed clinical characteristics of vitiligo, as outlined in recent consensus reports by vitiligo experts.
Objective: To determine vitiligo prevalence and detailed clinical characteristics in a Saudi cohort.
Cureus
November 2024
Internal Medicine and Clinical Immunology, Lebanese Hospital Geitaoui - University Medical Center, Beirut, LBN.
Bullous pemphigoid (BP) is the most prevalent autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and manifests with pruritus and localized or, most commonly, generalized bullous lesions. Numerous studies have established the association between BP and oral antidiabetic agents, particularly dipeptidyl peptidase 4 (DPP4) inhibitors, diuretics, and certain antibiotics, notably levofloxacin and cephalexin.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Nephrology, West China Hospital of Sichuan University, Chengdu, China.
Background And Objective: Uremic pruritus is a persistent condition that is difficult to cure in patients with end-stage renal disease who are having regular dialysis. It is highly prevalent, and current therapies have limited effectiveness and can cause significant adverse effects. Several trials have provided evidence that difelikefalin can be an effective treatment for uremic pruritus, with few side responses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!